|
1
|
Peairs KS, Choi Y, Stewart RW and Sateia
HF: Screening for breast cancer. Semin Oncol. 44:60–72. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reddy KB: MicroRNA (miRNA) in cancer.
Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Areeb Z, Stylli SS, Koldej R, Ritchie DS,
Siegal T, Morokoff AP, Kaye AH and Luwor RB: MicroRNA as potential
biomarkers in glioblastoma. J Neurooncol. 125:237–248. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohtsuka M, Ling H, Doki Y, Mori M and
Calin GA: MicroRNA processing and human cancer. J Clin Med.
4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lei ST, Shen F, Chen JW, Feng JH, Cai WS,
Shen L, Hu ZW and Xu B: MiR-639 promoted cell proliferation and
cell cycle in human thyroid cancer by suppressing CDKN1A
expression. Biomed Pharmacother. 84:1834–1840. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao X, Lu C, Chu W, Zhang B, Zhen Q, Wang
R, Zhang Y, Li Z, Lv B, Li H and Liu J: MicroRNA-124 suppresses
proliferation and glycolysis in non-small cell lung cancer cells by
targeting AKT-GLUT1/HKII. Tumour Biol. 39:10104283177062152017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu K, Xie F, Gao A, Zhang R, Zhang L,
Xiao Z, Hu Q, Huang W, Huang Q, Lin B, et al: SOX2 regulates
multiple malignant processes of breast cancer development through
the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis. Mol Cancer. 16:622017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sharma S, Nagpal N, Ghosh PC and
Kulshreshtha R: P53-miR-191-SOX4 regulatory loop affects apoptosis
in breast cancer. RNA. 23:1237–1246. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Muluhngwi P, Krishna A, Vittitow SL,
Napier JT, Richardson KM, Ellis M, Mott JL and Klinge CM: Tamoxifen
differentially regulates miR-29b-1 and miR-29a expression depending
on endocrine-sensitivity in breast cancer cells. Cancer Lett.
388:230–238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Z, Song X, Tian H, Miao Y, Feng X,
Li Y and Wang H: MicroRNA-137 inhibits growth of glioblastoma
through EGFR suppression. Am J Transl Res. 9:1492–1499.
2017.PubMed/NCBI
|
|
13
|
Hu S, Chen H, Zhang Y, Wang C, Liu K, Wang
H and Luo J: MicroRNA-520c inhibits glioma cell migration and
invasion by the suppression of transforming growth factor-β
receptor type 2. Oncol Rep. 37:1691–1697. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mesci A, Huang X, Taeb S, Jahangiri S, Kim
Y, Fokas E, Bruce J, Leong HS and Liu SK: Targeting of CCBE1 by
miR-330-3p in human breast cancer promotes metastasis. Br J Cancer.
116:1350–1357. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang H, Zhi H, Ma D and Li T: MiR-217
promoted the proliferation and invasion of glioblastoma by
repressing YWHAG. Cytokine. 92:93–102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu M, Kong X, Wang H, Huang G, Ye C and He
Z: A novel microRNAs expression signature for hepatocellular
carcinoma diagnosis and prognosis. Oncotarget. 8:8775–8784. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Chong CC, Chen GG and Lai PB: A
Seven-microRNA expression signature predicts survival in
hepatocellular carcinoma. PLoS One. 10:e01286282015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagy Á, Lánczky A, Menyhárt O and Győrffy
B: Validation of miRNA prognostic power in hepatocellular carcinoma
using expression data of independent datasets. Sci Rep. 8:92272018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
20
|
Chiang HR, Schoenfeld LW, Ruby JG, Auyeung
VC, Spies N, Baek D, Johnston WK, Russ C, Luo S, Babiarz JE, et al:
Mammalian microRNAs: Experimental evaluation of novel and
previously annotated genes. Genes Dev. 24:992–1009. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gu Y, Cheng Y, Song Y, Zhang Z, Deng M,
Wang C, Zheng G and He Z: MicroRNA-493 suppresses tumor growth,
invasion and metastasis of lung cancer by regulating E2F1. PLoS
One. 9:e1026022014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin S, Dai Y, Li C, Fang X, Han H and Wang
D: MicroRNA-544 inhibits glioma proliferation, invasion and
migration but induces cell apoptosis by targeting PARK7. Am J
Transl Res. 8:1826–1837. 2016.PubMed/NCBI
|
|
24
|
Zhang J, Fei B, Wang Q, Song M, Yin Y,
Zhang B, Ni S, Guo W, Bian Z, Quan C, et al: MicroRNA-638 inhibits
cell proliferation, invasion and regulates cell cycle by targeting
tetraspanin 1 in human colorectal carcinoma. Oncotarget.
5:12083–12096. 2014.PubMed/NCBI
|
|
25
|
Xiao M, Lou C, Xiao H, Yang Y, Cai X, Li
C, Jia S and Huang Y: MiR-128 regulation of glucose metabolism and
cell proliferation in triple-negative breast cancer. Br J Surg.
105:75–85. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu Y, Qin T, Li J, Wang L, Zhang Q, Jiang
Z and Mao J: MicroRNA-140-5p inhibits invasion and angiogenesis
through targeting VEGF-A in breast cancer. Cancer Gene Ther.
24:386–392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu Y, Luo W, Yang ZJ, Chi JR, Li YR, Ding
Y, Ge J, Wang X and Cao XC: miR-190 suppresses breast cancer
metastasis by regulation of TGF-β-induced epithelial-mesenchymal
transition. Mol Cancer. 17:702018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Villanueva CJ, Waki H, Godio C, Nielsen R,
Chou WL, Vargas L, Wroblewski K, Schmedt C, Chao LC, Boyadjian R,
et al: TLE3 is a dual-function transcriptional coregulator of
adipogenesis. Cell Metab. 13:413–427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kokabu S, Nakatomi C, Matsubara T, Ono Y,
Addison WN, Lowery JW, Urata M, Hudnall AM, Hitomi S, Nakatomi M,
et al: The transcriptional co-repressor TLE3 regulates myogenic
differentiation by repressing the activity of the MyoD
transcription factor. J Biol Chem. 292:12885–12894. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bartlett JM, Nielsen TO, Gao D, Gelmon KA,
Quintayo MA, Starczynski J, Han L, Burnell MJ, Levine MN, Chen BE,
et al: TLE3 is not a predictive biomarker for taxane sensitivity in
the NCIC CTG MA.21 clinical trial. Br J Cancer. 113:722–728. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang RW, Zeng YY, Wei WT, Cui YM, Sun HY,
Cai YL, Nian XX, Hu YT, Quan YP, Jiang SL, et al: TLE3 represses
colorectal cancer proliferation by inhibiting MAPK and AKT
signaling pathways. J Exp Clin Cancer Res. 35:1522016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu L, Zhang Y, Wong CC, Zhang J, Dong Y,
Li X, Kang W, Chan FKL, Sung JJY and Yu J: RNF6 promotes colorectal
cancer by activating the Wnt/β-catenin pathway via ubiquitination
of TLE3. Cancer Res. 78:1958–1971. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Samimi G, Ring BZ, Ross DT, Seitz RS,
Sutherland RL, O'Brien PM, Hacker NF and Huh WK: TLE3 expression is
associated with sensitivity to taxane treatment in ovarian
carcinoma. Cancer Epidemiol Biomarkers Prev. 21:273–279. 2012.
View Article : Google Scholar : PubMed/NCBI
|
